Login to Your Account



Advaxis Uses Listeria Bug to Launch Attack on Cancer Cells

By Catherine Shaffer
Staff Writer

Wednesday, August 8, 2012

Advaxis Inc. reported positive preliminary results from a Phase II trial of its human papillomavirus (HPV) immunotherapy product, ADXS-HPV, at the American Society of Clinical Oncology meeting in Chicago this week.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription